Allarity Therapeutics Inc
NASDAQ:ALLR

Watchlist Manager
Allarity Therapeutics Inc Logo
Allarity Therapeutics Inc
NASDAQ:ALLR
Watchlist
Price: 0.9 USD -3.23% Market Closed
Market Cap: 13.6m USD

EV/EBITDA
Enterprise Value to EBITDA

0.2
Current
-324.2
Median
4.6
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0.2
=
Enterprise Value
-4.9m USD
/
EBITDA
-26m USD
EBITDA Growth EV/EBITDA to Growth
US
Allarity Therapeutics Inc
NASDAQ:ALLR
Average EV/EBITDA: 13
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.7
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.2 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -678 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A